An eighty-seven-year-old patient with synchronous intrahepatic cholangiocarcinoma and gastric adenocarcinoma achieved over thirty-eight months of progression-free survival following treatment with ...
A study in Cellular Oncology identifies GLUT1 as an immunometabolic regulator in intrahepatic cholangiocarcinoma, showing that its inhibition remodels the ...
In a retrospective MRI study of 74 patients, combining arterial non-enhancement with delayed phase signal homogeneity differentiated confluent hepatic fibrosis ...
Frontiers in Medicine has retracted a 2021 study on the long non-coding RNA SNHG12 in intrahepatic cholangiocarcinoma after the authors ...
A retrospective study of 99 patients found that a low preoperative modified Geriatric Nutritional Risk Index, which combines C-reactive protein ...
A multi-phase MRI deep learning model combined with clinical predictors differentiated hepatocellular carcinoma from mass-forming intrahepatic cholangiocarcinoma with AUCs of ...
A study in Journal of Translational Medicine shows that the tumor protein stratifin stabilizes PAK1 and activates MYC-driven NECTIN2 expression, ...
A nationwide audit of 64 liver transplant patients with cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma confirms that very small intrahepatic tumours achieve ...
Researchers have identified the lipid sphingomyelin (30:1; O2) as a blood-based biomarker that outperforms conventional tumor markers in distinguishing intrahepatic ...
In a compelling advancement for liver cancer therapeutics, researchers have unveiled a novel molecular axis involving Fibroblast Growth Factor 1 ...
